| Literature DB >> 32297692 |
Ioanna Mela1, Pedro P Vallejo-Ramirez1, Stanislaw Makarchuk1, Graham Christie1, David Bailey1, Robert M Henderson2, Hiroshi Sugiyama3,4, Masayuki Endo3,4, Clemens F Kaminski1.
Abstract
We report the use of DNA origami nanostructures, functionalized with aptamers, as a vehicle for delivering the antibacterial enzyme lysozyme in a specific and efficient manner. We test the system against Gram-positive (Bacillus subtilis) and Gram-negative (Escherichia coli) targets. We use direct stochastic optical reconstruction microscopy (dSTORM) and atomic force microscopy (AFM) to characterize the DNA origami nanostructures and structured illumination microscopy (SIM) to assess the binding of the origami to the bacteria. We show that treatment with lysozyme-functionalized origami slows bacterial growth more effectively than treatment with free lysozyme. Our study introduces DNA origami as a tool in the fight against antibiotic resistance, and our results demonstrate the specificity and efficiency of the nanostructure as a drug delivery vehicle.Entities:
Keywords: DNA nanostructures; antimicrobial; atomic force microscopy; bionanotechnology; dSTORM
Mesh:
Substances:
Year: 2020 PMID: 32297692 PMCID: PMC7496991 DOI: 10.1002/anie.202002740
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 16.823
Figure 1Schematic representation of the DNA origami nanostructure (left). Each of the 5 “wells” in the origami tile carries two biotinylated staples for the attachment of streptavidin and, subsequently, biotinylated lysozyme (right). Fourteen aptamers, hybridized with staples at the four sides of the DNA origami, drive the attachment of the nanostructures to the bacterial targets. Four Alexa 647 molecules act as detection beacons for the nanostructure.
Figure 2a) 2D (left) and 3D (right) atomic force microscopy images of DNA origami nanostructures before any incubation (top), after incubation with streptavidin (middle), and after successive incubations with streptavidin and biotinylated lysozyme (bottom) (height scale 0–3.5 nm, from darker to lighter). b) Cross‐sections of the nanostructures shown in (a) show the height change at the wells before any incubation (blue), after incubation with streptavidin (green) and after successive incubations with streptavidin and biotinylated lysozyme (red). c) Volume measurements of the particles bound to the DNA origami structures after incubation with streptavidin alone and streptavidin and biotinylated lysozyme. d) dSTORM super‐resolution microscopy images of Alexa 647 fluorophores in the DNA origami nanostructures.
Figure 3a) SIM imaging demonstrates that DNA origami binds to E. coli. DNA origami is magenta and GFP‐expressing E. coli are green, while the overlapping areas are in white. b) SIM imaging demonstrating that DNA origami binds to B. subtilis. DNA origami is magenta and B. subtilis green, with overlapping areas in white. c) The mean coverage for E. coli is 18.6 %, and 22.5 % for B. subtilis. d) E. coli and e) B. subtilis that were incubated with DNA origami that did not carry aptamers. f) SIM image of L. lactis incubated with aptamer‐functionalized DNA origami.
Figure 4a) Averaged growth curves for B. subtilis (n=9). b) Growth rate analysis for B. subtilis. c) Averaged growth curves for E. coli (n=9). d) Growth rate analysis for E. coli. All the origami nanostructures used in those experiments were functionalized with aptamers. Error bars in each graph represent the standard error of the means.